Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732837 | 0.85 | TBXAS1 (0.61) | TBXAS1LMNARECQLFDPSNAPRT | |
| SCHEMBL266473 | 0.85 | TBXAS1 (0.80) | TBXAS1LMNAFDPSNAPRTCYP3A4 | |
| SCHEMBL14732861 | 0.85 | TBXAS1 (0.80) | TBXAS1LMNAFDPSNAPRTCYP3A4 | |
| SCHEMBL14732863 | 0.85 | TBXAS1 (0.61) | TBXAS1LMNARECQLFDPSNAPRT | |
| SCHEMBL15947894 | 0.85 | TBXAS1 (0.80) | TBXAS1LMNAFDPSNAPRTCYP3A4 | |
| SCHEMBL934603 | 0.84 | PSMB5 (0.53) | TBXAS1 | |
| SCHEMBL933922 | 0.83 | MKNK1 (0.55) | TBXAS1LMNA | |
| Hydrochloric Acid SCHEMBL27527974 | 0.81 | TBXAS1 (0.57) | TBXAS1LMNARECQLFDPSNAPRT | |
| Hydrochloric Acid SCHEMBL27580147 | 0.81 | TBXAS1 (0.57) | TBXAS1LMNARECQLFDPSNAPRT | |
| SCHEMBL1799124 | 0.81 | RECQL (0.54) | TBXAS1RECQLFDPSNAPRTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | claimed |
| CN-105745198-B | Carboxymethyl piperidine derivative | 橘生药品工业株式会社 | 2018-09-21 | — | — | CN | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| CN-102834380-B | Inhibitors of protein kinases | ASTRAZENECA | 2015-04-01 | — | — | CN | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| CN-102834380-A | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH | 2012-12-19 | — | — | CN | disclosed |
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | TBXAS1 793/4885LMNA 1506/4885RECQL 484/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | TBXAS1 793/4885LMNA 1506/4885RECQL 484/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | TBXAS1 793/4885LMNA 1506/4885RECQL 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.